AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors

Biochemical and Biophysical Research Communications

Volumn 381, Issue 2, 2009, Pages 181-186

  Thewke, Douglas ^a   Freeman Anderson, Natalie ^a   Pickle, Theresa ^a   Netherland, Courtney ^a   Chilton, Courtney ^a  

^a East Tennessee State University   (United States)

Author keywords

7 ketocholesterol; ACAT; AM 251; Apoptosis; SR144528

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ACETYL LOW DENSITY LIPOPROTEIN; ACYL COENZYME A; CHOLESTEROL ACYLTRANSFERASE; COENZYME A TRANSFERASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FOAM CELL; LIVER MICROSOME; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; BORNANES; CELL LINE; CHOLESTEROL; ENZYME INHIBITORS; KETOCHOLESTEROLS; MACROPHAGES; MICE; PIPERIDINES; PYRAZOLES; STEROL O-ACYLTRANSFERASE;

EID: 61849125275     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.02.020     Document Type: Article

References (31)

1. Quehenberger O. Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. J. Lipid Res. 46 (2005) 1582-1590
2. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull Jr. W., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., and Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Am. Heart Assoc. Arterioscler. Thromb. 14 (1994) 840-856
3. Chang T.Y., Chang C.C., and Cheng D. Acyl-coenzymeA:cholesterol acyltransferase. Annu. Rev. Biochem. 66 (1997) 613-638
4. Miyazaki A., Sakai M., Sakamoto Y., and Horiuchi S. Acyl-coenzymeA:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. Curr. Opin. Investig. Drugs. 4 (2003) 1095-1099
5. Liu J., Thewke D.P., Su Y.R., Linton M.F., Fazio S., and Sinensky M.S. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 174-179
6. Arai S., Shelton J.M., Chen M., Bradley M.N., Castrillo A., Bookout A.L., Mak P.A., Edwards P.A., Mangelsdorf D.J., Tontonoz P., and Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 1 (2005) 201-213
7. Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ. 11 Suppl.1 (2004) S12-S16
8. Chisolm G.M., Ma G., Irwin K.C., Martin L.L., Gunderson K.G., Linberg L.F., Morel D.W., and DiCorleto P.E. 7 beta-hydroperoxycholest-5-en-3 beta-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad. Sci. USA 91 (1994) 11452-11456
9. Brown A.J., and Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 142 (1999) 1-28
10. Freeman N.E., Rusinol A.E., Linton M., Hachey D.L., Fazio S., Sinensky M.S., and Thewke D. Acyl-coenzymeA:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. J. Lipid Res. 46 (2005) 1933-1943
11. Pertwee R.G., and Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 101-121
12. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22 (2001) 565-572
13. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2 (2002) 69-82
14. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., Karsak M., Zimmer A., Frossard J.L., and Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 (2005) 782-786
15. Freeman-Anderson N.E., Pickle T.G., Netherland C.D., Bales A., Buckley N.E., and Thewke D.P. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J. Lipid Res. (2008)
16. Rhee M.H., and Kim S.K. SR144528 as inverse agonist of CB2 cannabinoid receptor. J. Vet. Sci. 3 (2002) 179-184
17. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L., and 144528 S.R. the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
18. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
19. Clader J.W., Berger J.G., Burrier R.E., Davis H.R., Domalski M., Dugar S., Kogan T.P., Salisbury B., and Vaccaro W. Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J. Med. Chem. 38 (1995) 1600-1607
20. Lan R., Liu Q., Fan P., Lin S., Fernando S.R., McCallion D., Pertwee R., and Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42 (1999) 769-776
21. Namatame I., Tomoda H., Ishibashi S., and Omura S. Antiatherogenic activity of fungal beauveriolides inhibitors of lipid droplet accumulation in macrophages. Proc. Natl. Acad. Sci. USA 101 (2004) 737-742
22. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
23. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., Janiak P., and Herbert J.M. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7 (2005) 65-72
24. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
25. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
26. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
27. Scheen A.J., Van Gaal L.G., Despres J.P., Pi-Sunyer X., Golay A., and Hanotin C. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev. Med. Suisse 2 (2006) 1916-1923
28. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am. J. Med. 120 (2007) S18-S28 (discussion S29-S32)
29. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., Despres J.P., Kastelein J.J., Steinhubl S.R., Kapadia S., Yasin M., Ruzyllo W., Gaudin C., Job B., Hu B., Bhatt D.L., Lincoff A.M., and Tuzcu E.M. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
30. Dol-Gleizes F., Paumelle R., Visentin V., Mares A.M., Desitter P., Hennuyer N., Gilde A., Staels B., Schaeffer P., and Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 12-18
31. de Medina P., Payre B.L., Bernad J., Bosser I., Pipy B., Silvente-Poirot S., Favre G., Faye J.C., and Poirot M. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J. Pharmacol. Exp. Ther. 308 (2004) 1165-1173